1. JAK/STAT Signaling Stem Cell/Wnt Neuronal Signaling
  2. STAT Amyloid-β
  3. Colivelin

Colivelin 是一种具有大脑通透性的神经保护肽 (neuroprotective peptide),是 STAT3 的有效激活剂。Coliveli 通过激活 STAT3 在体外抑制神经元死亡。Colivelin 对神经毒性、Aβ 沉积,神经元细胞凋亡,在神经退行性疾病显示出长期有利的影响。Colivelin 具有潜力用于阿尔茨海默病和缺血性脑损伤的相关研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

Colivelin Chemical Structure

Colivelin Chemical Structure

CAS No. : 867021-83-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
500 μg ¥1350
In-stock
1 mg ¥2200
In-stock
5 mg 现货 询价
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Colivelin:

MCE 顾客使用本产品发表的 46 篇科研文献

WB

    Colivelin purchased from MCE. Usage Cited in: Aging. 2020 May 15;12(10):9066-9084.  [Abstract]

    The protein expression of the biomarkers of JAK-STAT signaling pathway. The expression of TNF-α, IFN-β, IL-6 and MCP-1 is all upregulated and IL-4 expression are downregulated in the group treated with miR-142-5p versus the NC group, and it could be rescued by Colivelin.

    查看 STAT 亚型特异性产品:

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro[1]. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease[2]. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury[1]

    IC50 & Target[1]

    STAT3

     

    Amyloid-β

     

    体外研究
    (In Vitro)

    Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm[1].
    Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN[1].
    Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition[4].
    Colivelin (50 µg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[4]

    Cell Line: BV-2 cells.
    Concentration: 50 µg/mL.
    Incubation Time: 4 hours.
    Result: Increased p-STAT3 levels.

    Cell Viability Assay[5]

    Cell Line: KYSE70 and TE8 cells.
    Concentration: 0.5 μM.
    Incubation Time: 1 hour (followed by CYT-Rx20 treatment)
    Result: Sgnificantly suppressed the viability in KYSE70 and TE8 cells.
    体内研究
    (In Vivo)

    Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42[1].
    Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit[1].
    Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: CD-1 mice[1]
    Dosage: 10 pmol/3 μl
    Administration: Intracerebroventricular administration
    Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons.
    Animal Model: C57 mice[1]
    Dosage: 1.4, 7, or 35 nM/0.21mL
    Administration: Intraperitoneal administration
    Result: Protected against cholinotoxin-induced amnesia in mice.
    Animal Model: Male C57BL/6 mice[3]
    Dosage: 1 mg/kg
    Administration: Intraperitoneal administration
    Result: Protected against ischemic brain injury, and improves neurological outcomes
    分子量

    2645.10

    Formula

    C119H206N32O35

    CAS 号
    性状

    固体

    颜色

    White to off-white

    Sequence Shortening

    SALLRSIPAPAGASRLLLLTGEIDLP

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Sealed storage, away from moisture

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 66.67 mg/mL (25.21 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 0.3781 mL 1.8903 mL 3.7806 mL
    5 mM 0.0756 mL 0.3781 mL 0.7561 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 2% DMSO    40% PEG300    5% Tween-80    53% Saline

      Solubility: ≥ 1 mg/mL (0.38 mM); 澄清溶液

    • 方案 二

      请依序添加每种溶剂: 2% DMSO    98% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1 mg/mL (0.38 mM); 澄清溶液

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.27%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 0.3781 mL 1.8903 mL 3.7806 mL 9.4514 mL
    5 mM 0.0756 mL 0.3781 mL 0.7561 mL 1.8903 mL
    10 mM 0.0378 mL 0.1890 mL 0.3781 mL 0.9451 mL
    15 mM 0.0252 mL 0.1260 mL 0.2520 mL 0.6301 mL
    20 mM 0.0189 mL 0.0945 mL 0.1890 mL 0.4726 mL
    25 mM 0.0151 mL 0.0756 mL 0.1512 mL 0.3781 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Colivelin
    目录号:
    HY-P1061
    需求量: